Galectin Therapeutics (GALT) Free Cash Flow (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Free Cash Flow of -$3.9 million for Q1 2026, up 49.72% year-over-year from -$2.6 million in Q1 2025, and up 36.62% quarter-over-quarter from -$6.1 million in Q4 2025.
Galectin Therapeutics (GALT) Free Cash Flow (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$3.9 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 49.72% year-over-year to -$3.9 million; the TTM figure through Mar 2026 stood at -$20.1 million (up 46.25% YoY), while the FY2025 annual figure was -$23.9 million, up 42.78% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$3.9 million, up from -$6.1 million in the prior quarter.
- The five-year high for Free Cash Flow was -$3.5 million in Q3 2025, with the low at -$12.8 million in Q4 2024.
- The 5-year median for Free Cash Flow is -$7.7 million (2025), against an average of -$7.9 million.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow plunged 170.02% in 2024, then soared 59.19% in 2025.
- Galectin Therapeutics' Free Cash Flow stood at -$7.2 million in 2022, then jumped by 34.56% to -$4.7 million in 2023, then slumped by 170.02% to -$12.8 million in 2024, then jumped by 52.31% to -$6.1 million in 2025, then surged by 36.62% to -$3.9 million in 2026.
- Business Quant data shows GALT's Free Cash Flow at -$3.9 million in Q1 2026, -$6.1 million in Q4 2025, and -$3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | -3.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.87 Mn |
| Mar 31, 2026 | -3.87 Mn |
| Dec 31, 2025 | -6.10 Mn |
| Dec 31, 2025 | -6.10 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Sep 30, 2025 | -3.50 Mn |
| Jun 30, 2025 | -6.61 Mn |
| Jun 30, 2025 | -6.61 Mn |
| Mar 31, 2025 | -7.69 Mn |
| Mar 31, 2025 | -7.69 Mn |
| Dec 31, 2024 | -12.79 Mn |
| Dec 31, 2024 | -12.79 Mn |
| Sep 30, 2024 | -8.58 Mn |
| Sep 30, 2024 | -8.58 Mn |
| Jun 30, 2024 | -8.30 Mn |
| Jun 30, 2024 | -8.30 Mn |
| Mar 31, 2024 | -12.10 Mn |
| Mar 31, 2024 | -12.10 Mn |
| Dec 31, 2023 | -4.74 Mn |
| Dec 31, 2023 | -4.74 Mn |